Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Benralizumab

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT00852943CompletedPrimary

Screening Protocol for Genetic Diseases of Allergic Inflammation

NCT06512883Phase 3Recruiting

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT07772388Completed

New Cases of EoE in Children in Poland.

Showing all 3 trials

Research Network

Common Treatments

  • Benralizumab1
  • Data Collection1

Active Sponsors

  • Medical University of Warsaw1
  • Astrazeneca AB1
  • AstraZeneca1
  • National Institute of Allergy and Infectious Diseases (NIAID)1

Top Investigators

Related Conditions

  • Hats1
  • Urticaria Anaphylaxis1
  • Eosinophilic Esophagitis Eoe1
  • Immune Deficiency1
  • Pediatric1

Activity Timeline